Management of Hyperleukocytosis in Pediatric Patients

Pathophysiology and Risk Stratification

Hyperleukocytosis causes life-threatening complications through distinct mechanisms, including rheological problems, intravascular micro-thrombosis, hemorrhage risk, and metabolic derangements, according to the American Society of Hematology 1, 2
The American Academy of Pediatrics recommends that pediatric patients with hyperleukocytosis (WBC >100 × 10⁹/L) should be immediately started on aggressive intravenous hyperhydration (2.5-3 liters/m²/day) titrated to fluid balance and clinical status, combined with hydroxyurea (25-50 mg/kg/day in 2-3 divided doses), with leukapheresis or exchange transfusion reserved for emergency organ-threatening leukostasis (cerebral, pulmonary, or priapism) 1, 2
The National Comprehensive Cancer Network guidelines state that critical distinction by leukemia type is necessary, as in acute myeloid leukemia (AML), particularly monocytic/myelomonocytic subtypes (FAB M4/M5), hyperleukocytosis carries significantly higher early mortality (23% vs 5% in ALL) due to intracerebral hemorrhage and pulmonary leukostasis 4

The American Society of Clinical Oncology recommends that for all patients with hyperleukocytosis (WBC >100 × 10⁹/L), intravenous hyperhydration (2.5-3 liters/m²/day) should be initiated, titrated to fluid balance, clinical status, and WBC count, along with hydroxyurea (25-50 mg/kg/day in 2-3 divided doses) 1, 2, 5
The European Society for Medical Oncology guidelines suggest that monitoring for tumor lysis syndrome is crucial, with checks for uric acid, LDH, potassium, phosphate, and calcium 2, 6

The American Urological Association recommends that for priapism, simultaneous interventions are required, including rapid leukoreduction via exchange transfusion or leukapheresis, urological emergency management with penile puncture and blood aspiration from cavernous tissue, followed by saline flushing 2, 3
The International Society on Thrombosis and Haemostasis guidelines state that for bleeding despite normal/elevated platelets, the mechanism is often acquired von Willebrand syndrome (AVWS) in patients with high platelet counts, and management includes desmopressin for mild bleeding and fresh frozen plasma, von Willebrand factor concentrates, intravenous immunoglobulin, or recombinant factor VIIa for severe bleeding 2, 3

The American College of Cardiology recommends that leukapheresis effectiveness should be evaluated, with marked cytoreduction achieved within 24 hours in all patients without procedure-related adverse events in single-center experience 6
The National Institute of Health guidelines suggest that management without leukapheresis can be successful using hyperhydration, allopurinol, strict monitoring, and early chemotherapy initiation, but the exact impact on short and long-term outcomes requires further multicenter evaluation 4